PMID- 19362168
OWN - NLM
STAT- MEDLINE
DCOM- 20091113
LR  - 20151119
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 9
IP  - 7-8
DP  - 2009 Jul
TI  - Protection of bleomycin-induced fibrosis and inflammation by taurine.
PG  - 971-7
LID - 10.1016/j.intimp.2009.04.003 [doi]
AB  - Taurine has been shown to protect against lung injury induced by various oxidants 
      including ozone, nitrogen dioxide, amiodarone, and paraquat and to protect 
      against bleomycin-induced lung injury in combination with niacin. In this study, 
      Spraque-Dawley rats were treated with 5% taurine in the drinking water for 10 
      days prior to bleomycin instillation. Fibrosis in the rats pretreated with 
      taurine (BT) was absent, along with fewer inflammatory infiltrates compared to 
      the untreated rats (BW). A significant decrease in the number of PMNs and a 
      decrease in hydroxyproline levels were found in the bronchoalveolar lavage fluid 
      in the BT group compared to the BW group. By immunohistochemical staining, 
      inducible nitric oxide synthase was evident in the lungs of bleomycin-treated 
      rats, and minimal when rats were treated with taurine. Tumor necrosis 
      factor-alpha (TNF-alpha) as measured by immunohistochemical staining, was present 
      in lungs of both taurine-treated and untreated rats, but was more abundant in the 
      BW group compared to the BT group. In addition, decreased ICAM presentation was 
      detected by EM immunogold staining in the BT group compared to the BW group. 
      These data demonstrate that rats pretreated with 5% taurine in their drinking 
      water prior to bleomycin instillation are protected from fibrosis, inflammatory 
      infiltrates, as well as nitric oxide and TNF-alpha production, which are 
      hallmarks of bleomycin lung injury.
FAU - Schuller-Levis, Georgia
AU  - Schuller-Levis G
AD  - Department of Immunology, New York State Institute for Basic Research in 
      Developmental Disabilities, Staten Island, New York 10314, USA. 
      georgial_levis@yahoo.com
FAU - Gordon, Ronald E
AU  - Gordon RE
FAU - Wang, Chuanhua
AU  - Wang C
FAU - Park, Seung Yong
AU  - Park SY
FAU - Park, Eunkyue
AU  - Park E
LA  - eng
GR  - HL-49942/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20090409
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 11056-06-7 (Bleomycin)
RN  - 1EQV5MLY3D (Taurine)
RN  - 2679MF687A (Niacin)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type II)
SB  - IM
MH  - Animals
MH  - Bleomycin/adverse effects
MH  - Cell Movement/drug effects
MH  - Chemotaxis/drug effects
MH  - Chromatography, High Pressure Liquid
MH  - Cytoprotection/drug effects
MH  - Drug Antagonism
MH  - Drug Therapy, Combination
MH  - Female
MH  - Fibrosis/chemically induced/immunology/*prevention & control
MH  - Inflammation
MH  - Leukocytes, Mononuclear/drug effects/immunology/*metabolism/pathology
MH  - Lung/drug effects/immunology/*metabolism/pathology
MH  - Macrophages, Alveolar/drug effects/immunology/*metabolism/pathology
MH  - Microscopy, Electron
MH  - Niacin/administration & dosage
MH  - Nitric Oxide Synthase Type II/genetics/immunology/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Taurine/*administration & dosage
MH  - Tumor Necrosis Factor-alpha/genetics/immunology/metabolism
EDAT- 2009/04/14 09:00
MHDA- 2009/11/17 06:00
CRDT- 2009/04/14 09:00
PHST- 2008/12/18 00:00 [received]
PHST- 2009/04/03 00:00 [revised]
PHST- 2009/04/06 00:00 [accepted]
PHST- 2009/04/14 09:00 [entrez]
PHST- 2009/04/14 09:00 [pubmed]
PHST- 2009/11/17 06:00 [medline]
AID - S1567-5769(09)00133-7 [pii]
AID - 10.1016/j.intimp.2009.04.003 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2009 Jul;9(7-8):971-7. doi: 10.1016/j.intimp.2009.04.003. 
      Epub 2009 Apr 9.